pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$LENZLENZ Therapeutics, Inc.

$LENZ
Solana Beach, CA, USupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Marketed: 1
1Marketed
Marketed
aceclidine
Presbyopia

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Phase 3 Safety Study for the Treatment of Presbyopia Subjectscompletedn=362
  • phase1Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopiacompletedn=30
🐶 Hiring Signal
No open roles indexed yet — view LENZ Therapeutics, Inc. jobs →

News

  • 9 biotechs will cut at least half their California workforces
    Workforce reductions have hit over 1,000 biopharma employees in The Golden State year to date, with pink slips coming from small biotechs and large pharmas. Biotechs have been hit the hardest, with…
    biospace · 4h ago
  • Biopharma layoffs rise YOY in October but sharply trend down for 2026
    October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025…
    biospace · 7d ago
  • Ono's five failures; Lenz and Molecular Partners to lay off staff
    Plus, news about GSK, Ascletis, BioMarin, Rigerna and Hisun. Ono Pharma’s endocannabinoid modulator flunks five trials: The biotech’s ONO-1110 did not meet the primary endpoint in five separate Pha…
    endpoints · 20d ago
  • Migraine biotech Vedana Therapeutics makes its debut with $46M Series A
    Vedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments for…
    endpoints · 5mo ago
  • A new Westlake-backed biotech takes aim at migraines
    Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.
    biopharma_dive · 5mo ago
identifiers
ticker
$LENZ
SEC CIK
0001815776
country
US
source
sec_tickers
top tags
Ophthalmology1
mentioned in
5news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 58m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?